Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database

References

• Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7–e22. doi:10.1161/CIR.0000000000000792
   PubMed Web of Science ®Google Scholar
• Feng KY, Loungani RS, Rao VN, et al. Best practices for prognostic evaluation of a patient with transthyretin amyloid cardiomyopathy. journal article review. JACC CardioOncol. 2019;1(2):273–279. doi:10.1016/j.jaccao.2019.11.006
   PubMedGoogle Scholar
• Garcia-Pavia P, Bengel F, Brito D, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021;23(6):895–905. doi:10.1002/ejhf.2198
   PubMed Web of Science ®Google Scholar
• Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019;7(8):709–716. doi:10.1016/j.jchf.2019.04.010
   PubMed Web of Science ®Google Scholar
• Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872–2891. doi:10.1016/j.jacc.2019.04.003
   PubMed Web of Science ®Google Scholar
• Nativi-Nicolau J, Judge DP, Hoffman JE, et al. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. ESC Heart Fail. 2021;8:3875–3884. doi:10.1002/ehf2.13541
   PubMed Web of Science ®Google Scholar
• Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20(2):163–178. doi:10.1007/s10741-014-9462-7
   PubMed Web of Science ®Google Scholar
• Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circulation. 2019;12(9):e006075. doi:10.1161/CIRCHEARTFAILURE.119.006075
   PubMed Web of Science ®Google Scholar
• Rubin J, Maurer MS. Cardiac amyloidosis: overlooked, underappreciated, and treatable. Annu Rev Med. 2020;71:203–219. doi:10.1146/annurev-med-052918-020140
   PubMed Web of Science ®Google Scholar
• Teng C, Li P, Bae JY, Pan S, Dixon RAF, Liu Q. Diagnosis and treatment of transthyretin-related amyloidosis cardiomyopathy. Clin Cardiol. 2020;43(11):1223–1231. doi:10.1002/clc.23434
   PubMed Web of Science ®Google Scholar
• Hanna M, Damy T, Grogan M, et al. Impact of tafamidis on health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Am J Cardiol. 2021;141:98–105. doi:10.1016/j.amjcard.2020.10.066
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis; 2021. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatments-heart-disease-caused-serious-rare-disease-transthyretin-mediated. Accessed November 10, 2021.
   Google Scholar
• Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629–9634. doi:10.1073/pnas.1121005109
   PubMed Web of Science ®Google Scholar
• Park J, Egolum U, Parker S, Andrews E, Ombengi D, Ling H. Tafamidis: a first-in-class transthyretin stabilizer for transthyretin amyloid cardiomyopathy. Ann Pharmacother. 2020;54(5):470–477. doi:10.1177/1060028019888489
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. doi:10.1056/NEJMoa1805689
   PubMed Web of Science ®Google Scholar
• Sabaté E. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization; 2003:198.
   Google Scholar
• Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–3035. doi:10.1161/CIRCULATIONAHA.108.768986
   PubMed Web of Science ®Google Scholar
• Leslie KH, McCowan C, Pell JP. Adherence to cardiovascular medication: a review of systematic reviews. J Public Health. 2019;41(1):e84–e94. doi:10.1093/pubmed/fdy088
   Web of Science ®Google Scholar
• van Onzenoort HAW, Menger FE, Neef C, et al. Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension. 2011;58(4):573–578. doi:10.1161/HYPERTENSIONAHA.111.171074
   PubMed Web of Science ®Google Scholar
• Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–314. doi:10.4065/mcp.2010.0575
   PubMed Web of Science ®Google Scholar
• Vong C, Boucher M, Riley S, Harnisch LO. Modeling of survival and frequency of cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy treated with tafamidis. Am J Cardiovasc Drugs. 2021;21(5):535–543. doi:10.1007/s40256-021-00464-y
   PubMed Web of Science ®Google Scholar
• Brixner D, Rubin DT, Mease P, et al. Patient support program increased medication adherence with lower total health care costs despite increased drug spending. J Manag Care Spec Pharm. 2019;25(7):770–779. doi:10.18553/jmcp.2019.18443
   PubMed Web of Science ®Google Scholar
• Rymer JA, Fonseca E, Bhandary DD, Kumar D, Khan ND, Wang TY. Difference in medication adherence between patients prescribed a 30-day versus 90-day supply after acute myocardial infarction. J Am Heart Assoc. 2021;10(1):e016215. doi:10.1161/JAHA.119.016215
   PubMed Web of Science ®Google Scholar
• Symphony Health. What we do. Available from: https://symphonyhealth.com/what-we-do. Accessed February 23, 2022.
   Google Scholar
• Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies–report of the ISPOR task force on retrospective databases. Value Health. 2003;6(2):90–97. doi:10.1046/j.1524-4733.2003.00242.x
   PubMed Web of Science ®Google Scholar
• Orsini LS, Berger M, Crown W, et al. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-why, what, and how: recommendations and a road map from the real-world evidence transparency initiative. Value Health. 2020;23(9):1128–1136. doi:10.1016/j.jval.2020.04.002
   PubMed Web of Science ®Google Scholar
• Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3–12. doi:10.1111/j.1524-4733.2006.00139.x
   PubMed Web of Science ®Google Scholar
• Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7–8):1280–1288. doi:10.1345/aph.1H018
   PubMed Web of Science ®Google Scholar
• Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(8 Suppl 3):S11–21. doi:10.1097/MLR.0b013e31829b1d2a
   PubMed Web of Science ®Google Scholar
• Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303–2310. doi:10.1185/03007990903126833
   PubMed Web of Science ®Google Scholar
• Baroletti S, Dell’Orfano H. Medication adherence in cardiovascular disease. Circulation. 2010;121(12):1455–1458. doi:10.1161/CIRCULATIONAHA.109.904003
   PubMed Web of Science ®Google Scholar
• Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–7e1. doi:10.1016/j.amjmed.2011.12.013
   PubMed Web of Science ®Google Scholar
• Helder MR, Schaff HV, Nishimura RA, et al. Impact of incidental amyloidosis on the prognosis of patients with hypertrophic cardiomyopathy undergoing septal myectomy for left ventricular outflow tract obstruction. Am J Cardiol. 2014;114(9):1396–1399. doi:10.1016/j.amjcard.2014.07.058
   PubMed Web of Science ®Google Scholar
• Koike H, Hashimoto R, Tomita M, et al. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid. 2011;18(2):53–62. doi:10.3109/13506129.2011.565524
   PubMed Web of Science ®Google Scholar
• Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16–26. doi:10.1161/circulationaha.118.038169
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–1212. doi:10.1161/circulationaha.108.843334
   PubMed Web of Science ®Google Scholar
• Russo M, Mazzeo A, Stancanelli C, et al. Transthyretin-related familial amyloidotic polyneuropathy: description of a cohort of patients with Leu64 mutation and late onset. J Peripher Nerv Syst. 2012;17(4):385–390. doi:10.1111/j.1529-8027.2012.00436.x
   PubMed Web of Science ®Google Scholar
• Siepen FAD, Bauer R, Voss A, et al. Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clin Res Cardiol. 2018;107(2):158–169. doi:10.1007/s00392-017-1167-1
   PubMed Web of Science ®Google Scholar
• Bruno M, Castaño A, Burton A, Grodin JL. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. Heart Fail Rev. 2021;26(1):35–45. doi:10.1007/s10741-020-10010-8
   PubMed Web of Science ®Google Scholar
• Kroi F, Fischer N, Gezin A, Hashim M, Rozenbaum MH. Estimating the gender distribution of patients with wild-type transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. Cardiol Ther. 2021;10(1):41–55. doi:10.1007/s40119-020-00205-3
   PubMed Web of Science ®Google Scholar
• Gilstrap LG, Dominici F, Wang Y, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail. 2019;12(6):e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407
   PubMed Web of Science ®Google Scholar
• Gerber BS, Cho YI, Arozullah AM, Lee SY. Racial differences in medication adherence: a cross-sectional study of Medicare enrollees. Am J Geriatr Pharmacother. 2010;8(2):136–145. doi:10.1016/j.amjopharm.2010.03.002
   PubMedGoogle Scholar
• De Geest S, Zullig LL, Dunbar-Jacob J, Hughes D, Wilson IB, Vrijens B. Improving medication adherence research reporting: ESPACOMP Medication Adherence Reporting Guideline (EMERGE). Eur J Cardiovasc Nurs. 2019;18(4):258–259. doi:10.1177/1474515119830298
   PubMed Web of Science ®Google Scholar
• Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705. doi:10.1111/j.1365-2125.2012.04167.x
   PubMed Web of Science ®Google Scholar
• Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047. doi:10.1155/2015/217047
   PubMed Web of Science ®Google Scholar
• Kronish IM, Thorpe CT, Voils CI. Measuring the multiple domains of medication nonadherence: findings from a Delphi survey of adherence experts. Transl Behav Med. 2021;11(1):104–113. doi:10.1093/tbm/ibz133
   PubMed Web of Science ®Google Scholar
• Masri A, Chen H, Wong C, et al. Initial experience prescribing commercial tafamidis, the most expensive cardiac medication in history. JAMA Cardiol. 2020;5(9):1066–1067. doi:10.1001/jamacardio.2020.1738
   PubMed Web of Science ®Google Scholar
• Lafeuille MH, Grittner AM, Lefebvre P, et al. Adherence patterns for Abiraterone acetate and concomitant prednisone use in patients with prostate cancer. J Manag Care Spec Pharm. 2014;20(5):477–484. doi:10.18553/jmcp.2014.20.5.477
   PubMed Web of Science ®Google Scholar
• Patel AK, Duh MS, Barghout V, et al. Real-world treatment patterns among patients with colorectal cancer treated with trifluridine/tipiracil and regorafenib. Clin Colorectal Cancer. 2018;17(3):e531–e539. doi:10.1016/j.clcc.2018.04.002
   PubMed Web of Science ®Google Scholar